HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Xin-Yan Pei Selected Research

7-hydroxystaurosporine (UCN 01)

2/2011Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
3/2008Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.
9/2007MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism.
5/2007Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
12/2006Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
6/2005The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
2/2005Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK.
4/2004Interruption of the NF-kappaB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Xin-Yan Pei Research Topics

Disease

12Multiple Myeloma
10/2014 - 04/2004
6Leukemia
06/2013 - 07/2004
6Mitochondrial Diseases (Mitochondrial Disease)
05/2007 - 04/2004
4Neoplasms (Cancer)
06/2017 - 03/2008
2Hematologic Neoplasms (Hematological Malignancy)
08/2012 - 07/2004
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
08/2008 - 07/2004
1Huntington Disease (Huntington's Disease)
09/2014
1Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
06/2013
1Polyploidy
08/2008
1Carcinoma (Carcinomatosis)
03/2008
1Breast Neoplasms (Breast Cancer)
03/2008

Drug/Important Bio-Agent (IBA)

87-hydroxystaurosporine (UCN 01)IBA
02/2011 - 04/2004
5Histone Deacetylase InhibitorsIBA
10/2014 - 06/2004
4Bortezomib (Velcade)FDA Link
10/2014 - 06/2004
3Pharmaceutical PreparationsIBA
06/2017 - 06/2005
3VorinostatFDA Link
06/2013 - 06/2004
3Histone Deacetylases (Histone Deacetylase)IBA
06/2013 - 06/2004
3alvocidib (flavopiridol)IBA
08/2012 - 07/2004
3Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
09/2008 - 02/2005
3CaspasesIBA
05/2007 - 04/2004
2Small Interfering RNA (siRNA)IBA
09/2014 - 06/2013
2Phosphotransferases (Kinase)IBA
06/2013 - 09/2011
2Checkpoint Kinase 1IBA
02/2011 - 12/2006
2Imatinib Mesylate (Gleevec)FDA Link
08/2008 - 07/2004
22- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamideIBA
03/2008 - 12/2006
2Farnesyltranstransferase (Farnesyltransferase)IBA
06/2005 - 02/2005
2Cyclin-Dependent Kinases (cdk Proteins)IBA
12/2004 - 07/2004
2Proteasome InhibitorsIBA
07/2004 - 06/2004
2Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
06/2004 - 04/2004
1Drug CombinationsIBA
06/2017
1Apoptosis Regulatory ProteinsIBA
01/2014
1MK-8776IBA
06/2013
1obatoclaxIBA
08/2012
1Serine (L-Serine)FDA Link
09/2011
1I-kappa B KinaseIBA
09/2011
1Dasatinib (BMS 354825)FDA Link
02/2011
1ABT-737IBA
12/2009
1tipifarnib (R115777)IBA
09/2008
1Aurora KinasesIBA
08/2008
1tozasertibIBA
08/2008
1DNA (Deoxyribonucleic Acid)IBA
08/2008
1TransferasesIBA
03/2008
1AZD 6244IBA
03/2008
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2007
1Lovastatin (Mevacor)FDA LinkGeneric
05/2007
1Simvastatin (Zocor)FDA LinkGeneric
05/2007
1FluvastatinFDA Link
05/2007
1Mitogen-Activated Protein Kinase 3IBA
12/2006
1MAP Kinase Kinase 1IBA
12/2006
1Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA
06/2005
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2005
1Caspase 8 (Caspase-8)IBA
02/2005
1Oxidants (Oxidizing Agents)IBA
12/2004
1Insulin-Like Growth Factor I (IGF-1)IBA
12/2004
1Dexamethasone (Maxidex)FDA LinkGeneric
12/2004
1ethyl 2- amino- 6- bromo- 4- (1- cyano- 2- ethoxy- 2- oxoethyl)- 4H- chromene- 3- carboxylateIBA
12/2004
1Cytochromes c (Cytochrome c)IBA
12/2004
1Interleukin-6 (Interleukin 6)IBA
12/2004
1Butyric Acid (Butanoic Acid)IBA
06/2004
1Reactive Oxygen Species (Oxygen Radicals)IBA
06/2004
1Caspase 9IBA
06/2004
1D-JNKI-1IBA
04/2004
1NF-kappa B (NF-kB)IBA
04/2004
13- (4- methylphenylsulfonyl)- 2- propenenitrileIBA
04/2004
1Poly Adenosine Diphosphate RiboseIBA
04/2004
1Peptides (Polypeptides)IBA
04/2004
1pyrazolanthroneIBA
04/2004

Therapy/Procedure

2Therapeutics
06/2017 - 08/2012